The title of the source editorial indicates a focus on how cellular metabolism, the immune system, and oncogenesis intersect, and on the implications of those intersections for drug discovery and development. The editorial format typically synthesizes current knowledge, highlights emerging concepts, and suggests directions for research and therapeutic innovation.
The provided source content, however, did not include the body of the editorial. The available material consisted of Frontiers in Immunology site navigation, journal sections, and other front-matter elements but not the editorial text itself. As a result, specific arguments, evidence summaries, or recommendations that the editorial may contain are not present here.
The page content supplied from the source is limited to journal infrastructure (about pages, section listings, submission links, and navigation). It repeatedly lists journal sections and site links but omits the editorial narrative, data, citations, figures, and conclusions.
Because the editorial text was not available in the provided material, the following detailed sections present general, conceptual information consistent with the editorial topic rather than a summary of the article’s specific content. Any concrete claims, study results, or author recommendations from the original editorial were not reported and therefore cannot be reproduced here.
Cancer cells reprogram metabolism to support proliferation, survival, and other hallmarks of malignancy. Common conceptual themes in this area include altered glucose metabolism, amino acid utilization, lipid synthesis, and mitochondrial function.
Although the specific metabolic pathways discussed in the editorial are not reported in the provided source, the general premise in this field is that metabolic reprogramming contributes to oncogenesis by supplying biosynthetic precursors, maintaining redox balance, and producing metabolites that influence signaling and epigenetics. These metabolic changes can be both drivers and enablers of malignant transformation and tumor progression.
The tumor microenvironment is metabolically distinct from normal tissue and can shape immune cell function. Immune cell activation, differentiation, and effector function are tightly coupled to metabolic programs; conversely, tumor metabolic activity can suppress or reprogram antitumor immunity via nutrient competition, accumulation of immunomodulatory metabolites, and changes in local oxygen tension.
Key conceptual considerations—reported widely in the literature though not in the provided source text—include how glucose, glutamine, fatty acids, and metabolic byproducts (for example, lactate) affect T cells, myeloid cells, and other immune populations. The editorial likely addresses these broad interactions, but the supplied page did not include those specifics.
Where metabolism and immune regulation converge, there are conceptual opportunities for therapeutic intervention. These can include:
Targeting tumor-specific metabolic enzymes or transporters to reduce tumor fitness while sparing normal cells.
Modulating immune cell metabolism to enhance antitumor responses, for example by supporting T cell persistence or reversing suppressive phenotypes in myeloid cells.
Targeting metabolic communication in the tumor microenvironment—such as neutralizing immunosuppressive metabolites or restoring nutrient availability to effector immune cells.
Combining metabolic modulators with established immunotherapies (e.g., checkpoint inhibitors) to overcome resistance mechanisms linked to metabolic constraints.
The editorial’s precise emphasis on particular targets, agents, or combinations was not available in the provided source content and therefore cannot be detailed here.
Translational paths in this conceptual space typically span target identification, validation in preclinical models that recapitulate tumor and immune metabolism, biomarker development to identify responsive patient subgroups, and rational combination strategies with existing therapies.
Practical development challenges often cited in the field include tumor heterogeneity, on-target toxicity in normal tissues that share metabolic pathways, and the need for dynamic biomarkers that reflect metabolic and immune states. Specific challenges or solutions proposed by the editorial were not reported in the supplied material.
The source page supplied here did not include the editorial text. To obtain the article’s full content, including any summarized evidence, mechanistic insights, proposed targets, or development recommendations, consult the complete article on the Frontiers in Immunology website using the provided DOI or article URL. Only the complete editorial will contain the authors’ original statements and any cited data that support their perspective.
Note: This rewrite preserves the editorial’s stated scope and intent but does not add or infer specific findings or recommendations that were not present in the provided source content.